In this webinar we will discuss:
- ● an overview of how pharmacogenomics can be used in oncology
- ● the difference between somatic and germline genetic testing
- ● the impact pharmacogenomics can have on chemotherapy and supportive care medication response
- ● the clinical utility of pharmacogenomic testing in oncology
About the speaker
Erica Schnettler, PhD is a Medical Science Liaison at OneOme. Dr. Schnettler received her B.S. in genetics from Iowa State University and PhD in pharmacology from the University of Minnesota Medical School. Her PhD research focused on ovarian cancer and understanding the role of the tumor microenvironment. As a research fellow at Mayo Clinic she studied the pharmacogenomics of anticancer agents including gemcitabine, triciribine, and temozolomide. She strongly believes precision medicine, specifically pharmacogenetics, is a valuable tool to optimize chemotherapy safety and efficacy, ultimately improving patient health outcomes.